The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia : A study by ERIC, the European research initiative on CLL
© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC..
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
American journal of hematology - 98(2023), 12 vom: 29. Dez., Seite 1856-1868 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ajh.27093 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362686246 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362686246 | ||
| 003 | DE-627 | ||
| 005 | 20231226091741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.27093 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362686246 | ||
| 035 | |a (NLM)37772428 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Visentin, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia |b A study by ERIC, the European research initiative on CLL |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. | ||
| 520 | |a In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Chatzikonstantinou, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Scarfò, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Kapetanakis, Anargyros |e verfasserin |4 aut | |
| 700 | 1 | |a Demosthenous, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Karakatsoulis, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Minga, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Chamou, Dimitra |e verfasserin |4 aut | |
| 700 | 1 | |a Allsup, David |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrero, Alejandro Alonso |e verfasserin |4 aut | |
| 700 | 1 | |a Andres, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Antic, Darko |e verfasserin |4 aut | |
| 700 | 1 | |a Baile, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Baliakas, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Besikli-Dimou, Sotiria |e verfasserin |4 aut | |
| 700 | 1 | |a Bron, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Chatzileontiadou, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Cordoba, Raul |e verfasserin |4 aut | |
| 700 | 1 | |a Correa, Juan-Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Cuéllar-García, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a De Paoli, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a De Paolis, Maria Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Dimou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Donaldson, David |e verfasserin |4 aut | |
| 700 | 1 | |a Catherwood, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Doubek, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Efstathopoulou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Eichhorst, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Elashwah, Salma |e verfasserin |4 aut | |
| 700 | 1 | |a Enrico, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Espinet, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Foglietta, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Frederiksen, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Fürstenau, Moritz |e verfasserin |4 aut | |
| 700 | 1 | |a García-Marco, José A |e verfasserin |4 aut | |
| 700 | 1 | |a García-Serra, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Collado, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Gimeno, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Glenthøj, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Maria Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Hakobyan, Yervand K |e verfasserin |4 aut | |
| 700 | 1 | |a Herishanu, Yair |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Rivas, José Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Herold, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Innocenti, Idanna |e verfasserin |4 aut | |
| 700 | 1 | |a Itchaki, Gilad |e verfasserin |4 aut | |
| 700 | 1 | |a Jaksic, Ozren |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Kalashnikova, Оlga B |e verfasserin |4 aut | |
| 700 | 1 | |a Kalicińska, Elżbieta |e verfasserin |4 aut | |
| 700 | 1 | |a Kater, Arnon P |e verfasserin |4 aut | |
| 700 | 1 | |a Kersting, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Labrador, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Lad, Deepesh |e verfasserin |4 aut | |
| 700 | 1 | |a Laurenti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Mark-David |e verfasserin |4 aut | |
| 700 | 1 | |a Lista, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Garcia, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Malerba, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Marasca, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Monia |e verfasserin |4 aut | |
| 700 | 1 | |a Marquet, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Mattsson, Mattias |e verfasserin |4 aut | |
| 700 | 1 | |a Mauro, Francesca R |e verfasserin |4 aut | |
| 700 | 1 | |a Morawska, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Motta, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Munir, Talha |e verfasserin |4 aut | |
| 700 | 1 | |a Murru, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Niemann, Carsten U |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Raquel Nunes |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Jacopo |e verfasserin |4 aut | |
| 700 | 1 | |a Orsucci, Lorella |e verfasserin |4 aut | |
| 700 | 1 | |a Papaioannou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlovsky, Miguel Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Piskunova, Inga |e verfasserin |4 aut | |
| 700 | 1 | |a Popov, Viola Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Quaglia, Francesca Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Quaresmini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Qvist, Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Rigolin, Gian Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Ruchlemer, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Šimkovič, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Špaček, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Sportoletti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Stanca, Oana |e verfasserin |4 aut | |
| 700 | 1 | |a Tadmor, Tamar |e verfasserin |4 aut | |
| 700 | 1 | |a Capasso, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Del Poeta, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Gutwein, Odit |e verfasserin |4 aut | |
| 700 | 1 | |a Karlsson, Linda Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Milosevic, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Mirás, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Reda, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Saghumyan, Gevorg |e verfasserin |4 aut | |
| 700 | 1 | |a Shrestha, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Te Raa, Doreen |e verfasserin |4 aut | |
| 700 | 0 | |a et al |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 98(2023), 12 vom: 29. Dez., Seite 1856-1868 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2023 |g number:12 |g day:29 |g month:12 |g pages:1856-1868 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.27093 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2023 |e 12 |b 29 |c 12 |h 1856-1868 | ||